Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 9/20 | 0.34 |
| ▸ | PPARG | P37231 | 8/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19929953 | 0.96 | ACACB (0.43) | ACACBPPARAPPARGABCB1PTPN1 | |
| SCHEMBL21288120 | 0.90 | ACACB (0.41) | ACACBPPARAPPARGABCB1PTPN1 | |
| SCHEMBL21288046 | 0.85 | ESR1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL21288164 | 0.76 | CA2 (0.32) | — | |
| SCHEMBL20363264 | 0.73 | ACACB (0.52) | ACACBPPARAPPARGABCB1PTPN1 | |
| SCHEMBL1703013 | 0.72 | ACACB (0.48) | ACACBPPARAPPARGABCB1MAPT | |
| SCHEMBL1709313 | 0.71 | PPARG (0.48) | ACACBPPARAPPARGPPARDELANE | |
| SCHEMBL20363241 | 0.71 | ACACB (0.50) | ACACBPPARAPPARGABCB1PTPN1 | |
| SCHEMBL27420078 | 0.70 | ACACB (0.49) | ACACBPPARAPPARGABCB1ALDH1A1 | |
| SCHEMBL12001199 | 0.68 | ACACB (0.79) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-03 | — | — | US | disclosed |
| US-20180064819-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20180064819-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | ACACB 773/4885PPARA 1589/4885PPARG 1743/4885 |
| US-20180064819-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | ACACB 773/4885PPARA 1589/4885PPARG 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.